The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

EHA 2022 | TakeAim Lymphoma: emavusertib + ibrutinib in R/R hematological malignancies

Erel Joffe • 30 Jun 2022

EHA 2022

TakeAim Leukemia TakeAim Lymphoma

Erel Joffe, MD, MSc, Tel Aviv Medical Center, Tel Aviv, Israel, and Memorial Sloan Kettering Cancer Center, New York, NY, comments on the mechanism of action of emavusertib, an IRAK4 inhibitor, and highlights the results of TakeAim Lymphoma, a Phase I study evaluating this drug in combination with ibrutinib in patients with relapsed/refractory (R/R) hematological malignancies (NCT03328078). Whilst the study reported promising efficacy results with two partial responders and two complete responders, it also reported occurrences of transient rhabdomyolysis. TakeAim Leukemia (NCT04278768), another study evaluating emavusertib in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) revealed that patients with specific spliceosome mutations may be more sensitive to this drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.